Express Pharma

MARCH 16, 2025

First, advanced research and development (R&D) and biologics will be critical. To move from generics to novel drug development, Indian companies must invest heavily in R&D for innovative therapies like biosimilars, cell and gene therapies, and specialty drugs. per cent of global patents to almost 2 per cent.

Biosimilars 98

Biosimilars Insurance Coverage and Processing Pharmaceutical Companies Pharmaceutical Companies 98

pharmaphorum

AUGUST 5, 2020

Importantly, multimorbidity occurs as clusters of diseases, and whilst there are different views on what the clusters are and how many exist, Lord says that most would agree there are three main clusters: Cardiovascular/metabolic – including heart disease, hypertension and Type 2 diabetes. Drug Discovery Today. The hallmarks of aging.

Hospitals 80

Hospitals Labelling Diabetes Drug Development 80

Express Pharma

NOVEMBER 1, 2024

In the marathon of drug development, where billions of dollars and over a decade of research are the norm, drug repurposing is quietly reshaping the landscape. Challenges in drug repurposing Despite these technological and regulatory advancements, the journey of drug repurposing is not without its challenges.

Drug Development 111

Drug Development Compounding Generic Medicine Vaccines 111

European Pharmaceutical Review

FEBRUARY 1, 2024

In this Q&A, he explores the trends and challenges within the cardiovascular treatment space, as well as clinical development of the company’s lead candidate obicetrapib, a cholesterol ester transfer protein (CETP) inhibitor for lowering low-density lipoprotein-cholesterol (LDL-C) and ultimately reducing cardiovascular risk.

Documentation 97

Documentation Diabetes Pharmaceutical Companies Pharmaceutical Companies 97